Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) had soared by 15.8% as of 12:06 p.m. ET on Friday. Did the clinical-stage biotech company report great news? Nope. Instead, the stock's gains ...

Potential delays in clinical trials may result in extended timelines for new drug approvals, and a sudden reduction in financial support could also lead to the loss of critical data if research teams ...

Robert F Kennedy Jr. has been confirmed as the new secretary of the Department of Health and Human Services (HHS) after a ...

Happy V-Day! Gorge on heart-shaped chocolate and ponder the implications of RFK Jr. being sworn in as health secretary. Today, we talk about that, as well as new cancer data from Corbus Pharma, Europe ...

Investors know the biotech industry is a waiting game—smaller companies in this space often work to secure the funding to ...

Corbus Pharmaceuticals has posted the first Western clinical data on its would-be rival to Pfizer’s Padcev. The overall ...

Moleculin Biotech (NASDAQ:MBRX – Get Free Report) was downgraded by stock analysts at Maxim Group from a “buy” rating to a “hold” rating in a report issued on Wednesday, MarketBeat reports. Separately ...

Relay Therapeutics' financial stability is strong, but zero Q3 2024 revenue and rising net losses raise concerns. Find out ...

Health scientists and drug industry executives around the world are on alert after the confirmation of Robert F. Kennedy Jr., who spreads antivaccine misinformation and has often derided the ...

Nuvation has a best-in-class lung cancer drug that could be approved in the US in June. Read why I'm bullish on the stock ...

What are "indirect costs" for universities? Why are some young scientists looking at opportunities abroad? And why are AI ...

Moleculin Biotech received FDA guidance reducing its Phase 3 trial size for Annamycin in AML. First unblinding is expected in ...